NasdaqCM:IMTXBiotechs
Assessing Immatics (NasdaqCM:IMTX) Valuation After Earnings Loss And Pipeline And Moderna Updates
Earnings Loss Puts Immatics in Focus
Immatics (NasdaqCM:IMTX) is back on investors’ radar after reporting a full year 2025 net loss of €196.45 million and a basic loss per share of €1.61 from continuing operations.
This earnings update comes alongside progress in its PRAME focused cell and bispecific therapies, ongoing Phase 3 work for anzu cel, and a collaboration with Moderna that recently triggered a milestone payment.
See our latest analysis for Immatics.
At a share price of US$9.86,...